MCLENA-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease

With the general population reaching higher ages, a surge in Alzheimer’s disease (AD) incidence will happen in the coming decades, putting a heavy burden on families and healthcare systems Worldwide. This emphasizes the pressing need for AD therapeutic interventions. Accumulating evidence indicates...

Descripción completa

Detalles Bibliográficos
Autores principales: Decourt, Boris, Wilson, Jeffrey, Ritter, Aaron, Dardis, Christopher, DiFilippo, Frank P, Zhuang, Xiaowei, Cordes, Dietmar, Lee, Garam, Fulkerson, Nadia D, St Rose, Tessa, Hartley, Katurah, Sabbagh, Marwan N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051033/
https://www.ncbi.nlm.nih.gov/pubmed/32123490
http://dx.doi.org/10.2147/oajct.s221914

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051033/
https://www.ncbi.nlm.nih.gov/pubmed/32123490
http://dx.doi.org/10.2147/oajct.s221914

Ejemplares similares